A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.
Clinical cancer research today often includes testing the value of biomarkers to direct treatment and for drug development. However, the practical challenges of integration of molecular information into clinical trial protocols are increasingly appreciated. Inherent difficulties include evidence gap...
Main Authors: | Hall, J, Salgado, R, Lively, T, Sweep, F, Schuh, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Lancet
2014
|
Similar Items
-
THE EORTC AND THE EORTC BREAST CANCER GROUP
by: Therasse Patrick
Published: (2005-01-01) -
Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group
by: Christoph Thomssen, et al.
Published: (2023-03-01) -
NCRI CTRad workshop: translating novel discoveries to and from the clinic
by: Hak, CCW, et al.
Published: (2023) -
Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL
by: Munir, T, et al.
Published: (2014) -
Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome
by: Eyre, TA, et al.
Published: (2015)